A Global Study of the PETAL Consortium
Recruiting · NCT06067347
Conditions: T-Cell and NK-Cell Neoplasm
At a glance
- Research payments reported, 2025
- $70,000
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 1,200
About the trial
- Sponsor
- Massachusetts General Hospital
- Dates
- Started 2024-01-05; completion 2028-01
- Results posted
- Not yet
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.
From ClinicalTrials.gov, last updated 2026-04-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $70,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.